3D Tissue Models
Inaugural Kinbase Inhibitors: Moving Forward into Clinical Studies Oct (16-17)
World Trade Center
200 Seaport Boulevard
Boston, MA
Inaugural Kinbase Inhibitors: Moving Forward into Clinical Studies 
Cambridge Healthtech Institute
World Trade Center

Schedule of Presentations:

Tuesday, October 16, 2007
07:30:00 Registration & Morning Coffee (07:30-08:30)
08:30:00 Sensitivity and Selectivity (08:30-10:40) Gitte Neubauer, Deborah Moshinsky, Bert Klebl
08:30:00 Sensitivity and Selectivity: Chairperson’s Remarks (08:30-08:40)
08:40:00 Sensitivity and Selectivity: Kinase Inhibitor Selectivity: Panel Screening and Application to Drug Discovery (08:40-09:10) Deborah Moshinsky
09:10:00 Sensitivity and Selectivity: Ex vivo Profiling of PI3K Inhibitors: A Translational Approach? (09:10-09:40) Gitte Neubauer
09:40:00 Sensitivity and Selectivity: An Old Story with New Impact - Selective Inhibition of Distinct CDKs from a Family of 13 Members (09:40-10:10) Bert Klebl
10:10:00 Sensitivity and Selectivity: Grand Opening Coffee Break in the Exhibit Hall (10:10-10:40)
10:40:00 The Challenge of Resistance and safety (10:40-12:10) Ariel Fernandez, Thomas Force, William Shakespeare
10:40:00 The Challenge of Resistance and safety: Structural Insights Into Bcr-Abl Kinase Domain Mutations and Drug Resistance: AP24534, A Potent Orally Active Inhibitor of T315I (10:40-11:10) William Shakespeare
11:10:00 The Challenge of Resistance and safety: Kinase Inhibitors and the Issue of Cardiac Toxicity (11:10-11:40) Thomas Force
11:40:00 The Challenge of Resistance and safety: Curbing the Cardiotoxicity of Kinase Inhibitors: The Methyl that Save the Heart (11:40-12:10) Ariel Fernandez
12:10:00 Clinical Trials: Topically Applied Kinase Inhibitors for the Treatment of Ocular Diseases (12:10-12:40) John Doukas
12:10:00 Clinical Trials (12:10-19:30) Robert S. McDowell, Robert Wilkinson, David Hangauer, Stephen D. Harrison, Tammie Yeh, Laura Thomson, John Doukas
12:40:00 Clinical Trials: Luncheon Workshop or Lunch on Your Own(12:40-13:10)
13:10:00 Clinical Trials: Session Break2:20 Chairperson’s Remarks (13:10-14:25) David Hangauer
14:25:00 Clinical Trials: The First Non-ATP Competitive Src Inhibitor to Enter Clinical Trials (14:25-14:55) David Hangauer
14:55:00 Clinical Trials: AZD1152, a Highly Potent and Selective Inhibitor of Aurora B Kinase (14:55-15:25) Robert Wilkinson
15:25:00 Clinical Trials: Technology Watch - The Targeted Proteins Database (TPdb) (15:25-15:40) Laura Thomson
15:40:00 Clinical Trials: Technology Watch (15:40-15:55)
15:55:00 Clinical Trials: Networking Refreshment Break in the Exhibit Hall (15:55-16:30)
16:30:00 Clinical Trials: Maintaining Mechanistic Fidelity of Kinase Inhibitors from Lead Identification to the Clinic (16:30-17:00) Robert S. McDowell
17:00:00 Clinical Trials: A Novel Approach to Selectively Targeting PKC Isozymes Yields Clinical Drug Candidates (17:00-17:30) Stephen D. Harrison
17:30:00 Clinical Trials: Preclinical and Early Clinical Development of AZD6244/ARRY-142886, a Potent, Highly Selective MEK1/2 Inhibitor (17:30-18:00) Tammie Yeh
18:00:00 Clinical Trials: Happy Hour in the Exhibit Hall (18:00-19:30)
19:30:00 End of Conference Day
Wednesday, October 17, 2007
07:30:00 Registration, Morning Coffee & Roundtable Discussion Sessions (07:30-08:30) Tomi Sawyer
08:30:00 Keynote Introduction (08:30-08:40)
08:40:00 Executive Panel: Delivering Drugs for Difficult Targets (08:40-09:40) Alexander Rod MacKenzie, John J. Rossi, Jesus Tito Gonzalez, Mikael Dolsten, Lex Van der Ploeg, Shama Kajiji
09:40:00 Networking Coffee Break in the Exhibit Hall (09:40-10:35)
10:35:00 New Therapeutics Scopes (10:35-12:40) Yujia Dai, Jean-Baptiste Telliez, John Doukas, Esteban Masuda
10:35:00 New Therapeutics Scopes: Chairperson’s Remarks (10:35-10:40)
10:40:00 New Therapeutics Scopes: The MK2/MK3 Pathway in Inflammation and Beyond (10:40-11:10) Jean-Baptiste Telliez
11:10:00 New Therapeutics Scopes: Syk Inhibitor Program for Inflammatory Diseases (11:10-11:40) Esteban Masuda
11:40:00 New Therapeutics Scopes: Multitargeted Receptor Tyrosine Kinase Inhibitor ABT-869--Discovery and Clinical Development (11:40-12:10) Yujia Dai
12:10:00 New Therapeutics Scopes: Topically Applied Kinase Inhibitors for the Treatment of Ocular Diseases (12:10-12:40) John Doukas
12:40:00 Close of Kinase Inhibitor Conference
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.